One injection could change how we treat fatty liver disease

Date:

Share this article:

Del denne artikel:

One shot under the skin was enough to push most patients' liver fat back into the normal range, a result no existing treatment has matched.

You probably know someone who has been told their liver numbers are a little off at a routine check-up.

Often there is no pain and nothing that feels wrong. Yet the fat has been building up quietly for years.

A first-in-human trial of a gene-silencing drug from Regeneron, published in the New England Journal of Medicine, has now shown that one injection can clear that fat in most patients.

By week 24, liver fat was back in the normal range in 79 percent of the treated patients.

Also read: Your packaged food label may be hiding how unhealthy the product really is

In 97 percent it had dropped by at least 30 percent. No one in the placebo group reached either mark.

The drug is called CIDEBsiRNA. It is designed to turn off a single gene in liver cells.

The trial involved 40 adults with fatty liver disease at two UK research centers. Thirty got a single dose under the skin and ten got placebo.

Why the CIDEB gene matters for fatty liver

CIDEB came out of a genetics hunt. Researchers noticed that people born with a broken copy of the gene tend to have less liver fat and a lower chance of fatty liver disease or cirrhosis.

Also read: Stronger flu shot linked to 55% lower Alzheimer's risk

The idea behind the drug is simple.

If missing CIDEB protects the liver naturally, dialing it down with a medicine should do something similar.

The condition the drug targets is metabolic dysfunction-associated steatotic liver disease, or MASLD, previously called NAFLD.

It is one of the most common chronic liver conditions worldwide.

Also read: The FDA just approved a first-of-its-kind daily pill to prevent repeat strokes

Around one in three adults is thought to have it, and most do not know.

Left alone, it can slowly scar the liver and lead to cirrhosis or liver cancer years later.

How well the single shot held up over nine months

The effect did not fade quickly. At week 36, mean liver fat was down by 58 to 80 percent across dose groups.

In 62 percent of treated patients it was back in the normal range.

Also read: Researchers find that BMI may misclassify obesity risk in thousands of adults

A key marker of liver inflammation, serum ALT, dropped about 32 percent by week 12. In the placebo group it rose by 5 percent.

Side effects came at similar rates in both groups, and no one dropped out of the trial.

There was no nausea or vomiting, a common complaint with some other fatty liver drugs in development.

What still has to be shown in bigger trials

This was a small Phase 1 trial, and safety was the main goal.

Also read: Signs your winter fatigue could actually be seasonal depression

Most participants did not have elevated liver enzymes or scarring to begin with, so the drug has not yet been tested in people with advanced disease.

Regeneron says Phase 2 and Phase 3 trials are now recruiting to check longer-term safety and whether the drug also heals the liver tissue itself.

Anyone told that their liver values are high should talk to a doctor about diet, weight and routine monitoring, which remain the mainstays of care today.

This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.

Other articles

Your packaged food label may be hiding how unhealthy the product really is

A new analysis compared what packaged food labels flag with what the government's own dietary guide actually says.

Stronger flu shot linked to 55% lower Alzheimer’s risk

For adults over 65, the preferred flu shot this season may turn out to offer something nobody expected.

The FDA just approved a first-of-its-kind daily pill to prevent repeat strokes

Stroke survivors now have a new daily pill that works through a clotting pathway older blood thinners never reached.

Researchers find that BMI may misclassify obesity risk in thousands of adults

A study just redrew the line between a health risk and an actual illness, with a tape measure at the center.

Your packaged food label may be hiding how unhealthy the product really is

A new analysis compared what packaged food labels flag with what the government's own dietary guide actually says.

Stronger flu shot linked to 55% lower Alzheimer’s risk

For adults over 65, the preferred flu shot this season may turn out to offer something nobody expected.

The FDA just approved a first-of-its-kind daily pill to prevent repeat strokes

Stroke survivors now have a new daily pill that works through a clotting pathway older blood thinners never reached.